BibTex RIS Cite

The importance of pretreatment performance status and LDH level in patients with stage III-IV nasopharyngeal carcinoma

Year 2009, Volume: 24 Issue: 2, 65 - 72, 01.03.2009

Vuslat Yürüt-çaloğlu Murat Çaloğlu Hakan Karagöl Ruşen Coşar-alas Zafer Koçak

Abstract

OBJECTIVES To evaluate the prognostic factors in patients treated with radiotherapy for locally advanced nasopharyngeal carcinoma. METHODS Forty-eight patients (37 males, 11 females) treated between September 1999 and September 2007 were assessed retrospectively. RESULTS Ten patients (21%) recurred loco-regionally. Gender (p=0.022), Eastern Cooperative Oncology Group (ECOG) performance status (PS) (p

Keywords

-

References

  • 1. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002;13(7):1007-15.
  • 2. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996;77(12):2423-31.
  • 3. al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J Clin Oncol 1990;8(8):1342-51.
  • 4. Cheng SH, Tsai SY, Horng CF, Yen KL, Jian JJ, Chan KY, et al. A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66(4):992-1003.
  • 5. Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest 2007;25(5):315-21.
  • 6. Dimery IW, Peters LJ, Goepfert H, Morrison WH, Byers RM, Guillory C, et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol 1993;11(10):1919-28.
  • 7. Garden AS, Lippman SM, Morrison WH, Glisson BS, Ang KK, Geara F, et al. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. Int J Radiat Oncol Biol Phys 1996;36(5):1005-12.
  • 8. Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, et al. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer 1997;79(7):1279-86.
  • 9. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19(5):1350-7.
  • 10. Liaw CC, Wang CH, Huang JS, Kiu MC, Chen JS, Chang HK. Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma. Acta Oncol 1997;36(2):159-64.
  • 11. Kolev Y, Uetake H, Takagi Y, Sugihara K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol 2008;15(8):2336-44.
  • 12. Swan F Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989;7(10):1518-27.
  • 13.Jørgensen LG, Osterlind K, Genollá J, Gomm SA, Hernández JR, Johnson PW, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996;74(3):463-7.
  • 14. Steyerberg EW, Keizer HJ, Fosså SD, Sleijfer DT, Bajorin DF, Donohue JP, et al. Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. Br J Cancer 1996;74(9):1492-8.
  • 15.Chatani M, Matayoshi Y, Masaki N. Radiation therapy of nasopharyngeal carcinoma: treatment results and prognostic factors. [Article in Japanese] Nippon Igaku Hoshasen Gakkai Zasshi 1993;53(8):945-52. [Abstract]
  • 16. Saif MW, A.D., et al., Serum alkaline phosphatase level as a prognostic tool in colorectal cancer: A study of 105 patients. J Appl Res 2005;5(1):88-95.
  • 17. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2005;61(4):1087-95.
  • 18. Fazekas JT, Scott C, Marcial V, Davis LW, Wasserman T, Cooper JS. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79- 15. Int J Radiat Oncol Biol Phys 1989;17(6):1177-81.
  • 19.Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798-804.
  • 20. Yurut-Caloglu, V, Caloglu, M. Treatment of anemia by recombinant human erythropoietin in cancer patients undergoing radiotherapy Asia-Pacific Journal of Clinical Oncology 2008;4(4):199-207.
  • 21. Petrovich Z, Kuisk H, Jose L, Barton RT. Advanced carcinoma of the nasopharynx. Treatment results. Acta Radiol Oncol 1981;20(4):245-51.

Evre III-IV nazofarinks kanseri tanılı hastalarda tedavi öncesi performans durumu ve LDH düzeyinin önemi

Year 2009, Volume: 24 Issue: 2, 65 - 72, 01.03.2009

Vuslat Yürüt-çaloğlu Murat Çaloğlu Hakan Karagöl Ruşen Coşar-alas Zafer Koçak

Abstract

AMAÇ Radyoterapi ile tedavi edilen evre III-IV nazofarinks kanserli hastalarda prognostik faktörler incelendi. GEREÇ VE YÖNTEM Eylül 1999-Eylül 2007 tarihleri arasında tedavi edilen 48 hasta (37 erkek, 11 kadın) geriye dönük olarak değerlendirildi. BULGULAR Lokal-bölgesel yineleme 10 (%21) hastada izlendi. Lokal-bölgesel kontrolü etkileyen faktörler; cinsiyet (p=0.022), Eastern Cooperative Oncology Group (ECOG) performans durumu (p < 0.0001), Hb (p=0.0035) ve LDH düzeyidir
(p=0.032). Multivariet analizde, sadece performans durumu
etkisini korumuştur (p=0.003). On sekiz (%38) hastada uzak
metastaz gelişti. Univariet analizde performans durumu
(p=0.022), Hb (p=0.002), ALP (p=0.004), LDH düzeyi
(p=0.007) ve RT’yi tamamlama (p=0.014) uzak metastaz
oluşmasını etkiledi. Multivariet analizde ise sadece LDH
düzeyi (p=0.001) etkinliğini korudu. Analiz sırasında 27
(%56) hastan›n hayatını kaybettiği saptandı. Univariet analizde
performans durumu (p=0.012), RT’yi tamamlama
(p < 0.0001), metastaz oluşması (p=0.018) ve LDH düzeyinin
(p=0.018) sağkalımı etkildiği görüldü. Multivariet analizde
yalnızca LDH düzeyi anlamlılığını korudu (p=0.026).

Keywords

LDH düzeyi nazofarinks kanseri performansdurumu radyoterapi

References

  • 1. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002;13(7):1007-15.
  • 2. Teo PM, Kwan WH, Lee WY, Leung SF, Johnson PJ. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996;77(12):2423-31.
  • 3. al-Sarraf M, Pajak TF, Cooper JS, Mohiuddin M, Herskovic A, Ager PJ. Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a radiation therapy oncology group study. J Clin Oncol 1990;8(8):1342-51.
  • 4. Cheng SH, Tsai SY, Horng CF, Yen KL, Jian JJ, Chan KY, et al. A prognostic scoring system for locoregional control in nasopharyngeal carcinoma following conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66(4):992-1003.
  • 5. Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest 2007;25(5):315-21.
  • 6. Dimery IW, Peters LJ, Goepfert H, Morrison WH, Byers RM, Guillory C, et al. Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol 1993;11(10):1919-28.
  • 7. Garden AS, Lippman SM, Morrison WH, Glisson BS, Ang KK, Geara F, et al. Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. Int J Radiat Oncol Biol Phys 1996;36(5):1005-12.
  • 8. Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, et al. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer 1997;79(7):1279-86.
  • 9. Ma J, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19(5):1350-7.
  • 10. Liaw CC, Wang CH, Huang JS, Kiu MC, Chen JS, Chang HK. Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma. Acta Oncol 1997;36(2):159-64.
  • 11. Kolev Y, Uetake H, Takagi Y, Sugihara K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann Surg Oncol 2008;15(8):2336-44.
  • 12. Swan F Jr, Velasquez WS, Tucker S, Redman JR, Rodriguez MA, McLaughlin P, et al. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol 1989;7(10):1518-27.
  • 13.Jørgensen LG, Osterlind K, Genollá J, Gomm SA, Hernández JR, Johnson PW, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996;74(3):463-7.
  • 14. Steyerberg EW, Keizer HJ, Fosså SD, Sleijfer DT, Bajorin DF, Donohue JP, et al. Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer. Br J Cancer 1996;74(9):1492-8.
  • 15.Chatani M, Matayoshi Y, Masaki N. Radiation therapy of nasopharyngeal carcinoma: treatment results and prognostic factors. [Article in Japanese] Nippon Igaku Hoshasen Gakkai Zasshi 1993;53(8):945-52. [Abstract]
  • 16. Saif MW, A.D., et al., Serum alkaline phosphatase level as a prognostic tool in colorectal cancer: A study of 105 patients. J Appl Res 2005;5(1):88-95.
  • 17. Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2005;61(4):1087-95.
  • 18. Fazekas JT, Scott C, Marcial V, Davis LW, Wasserman T, Cooper JS. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial #79- 15. Int J Radiat Oncol Biol Phys 1989;17(6):1177-81.
  • 19.Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338(25):1798-804.
  • 20. Yurut-Caloglu, V, Caloglu, M. Treatment of anemia by recombinant human erythropoietin in cancer patients undergoing radiotherapy Asia-Pacific Journal of Clinical Oncology 2008;4(4):199-207.
  • 21. Petrovich Z, Kuisk H, Jose L, Barton RT. Advanced carcinoma of the nasopharynx. Treatment results. Acta Radiol Oncol 1981;20(4):245-51.
There are 21 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Vuslat Yürüt-çaloğlu This is me

Murat Çaloğlu This is me

Hakan Karagöl This is me

Ruşen Coşar-alas This is me

Zafer Koçak This is me

Publication Date March 1, 2009
Published in Issue Year 2009 Volume: 24 Issue: 2

Cite

APA Yürüt-çaloğlu, V., Çaloğlu, M., Karagöl, H., Coşar-alas, R., et al. (2009). Evre III-IV nazofarinks kanseri tanılı hastalarda tedavi öncesi performans durumu ve LDH düzeyinin önemi. Türk Onkoloji Dergisi, 24(2), 65-72.
AMA Yürüt-çaloğlu V, Çaloğlu M, Karagöl H, Coşar-alas R, Koçak Z. Evre III-IV nazofarinks kanseri tanılı hastalarda tedavi öncesi performans durumu ve LDH düzeyinin önemi. Türk Onkoloji Dergisi. March 2009;24(2):65-72.
Chicago Yürüt-çaloğlu, Vuslat, Murat Çaloğlu, Hakan Karagöl, Ruşen Coşar-alas, and Zafer Koçak. “Evre III-IV Nazofarinks Kanseri tanılı Hastalarda Tedavi öncesi Performans Durumu Ve LDH düzeyinin önemi”. Türk Onkoloji Dergisi 24, no. 2 (March 2009): 65-72.
EndNote Yürüt-çaloğlu V, Çaloğlu M, Karagöl H, Coşar-alas R, Koçak Z (March 1, 2009) Evre III-IV nazofarinks kanseri tanılı hastalarda tedavi öncesi performans durumu ve LDH düzeyinin önemi. Türk Onkoloji Dergisi 24 2 65–72.
IEEE V. Yürüt-çaloğlu, M. Çaloğlu, H. Karagöl, R. Coşar-alas, and Z. Koçak, “Evre III-IV nazofarinks kanseri tanılı hastalarda tedavi öncesi performans durumu ve LDH düzeyinin önemi”, Türk Onkoloji Dergisi, vol. 24, no. 2, pp. 65–72, 2009.
ISNAD Yürüt-çaloğlu, Vuslat et al. “Evre III-IV Nazofarinks Kanseri tanılı Hastalarda Tedavi öncesi Performans Durumu Ve LDH düzeyinin önemi”. Türk Onkoloji Dergisi 24/2 (March 2009), 65-72.
JAMA Yürüt-çaloğlu V, Çaloğlu M, Karagöl H, Coşar-alas R, Koçak Z. Evre III-IV nazofarinks kanseri tanılı hastalarda tedavi öncesi performans durumu ve LDH düzeyinin önemi. Türk Onkoloji Dergisi. 2009;24:65–72.
MLA Yürüt-çaloğlu, Vuslat et al. “Evre III-IV Nazofarinks Kanseri tanılı Hastalarda Tedavi öncesi Performans Durumu Ve LDH düzeyinin önemi”. Türk Onkoloji Dergisi, vol. 24, no. 2, 2009, pp. 65-72.
Vancouver Yürüt-çaloğlu V, Çaloğlu M, Karagöl H, Coşar-alas R, Koçak Z. Evre III-IV nazofarinks kanseri tanılı hastalarda tedavi öncesi performans durumu ve LDH düzeyinin önemi. Türk Onkoloji Dergisi. 2009;24(2):65-72.